Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

196.63B

Market cap196.63B

Price-Earnings ratio

10.30

Price-Earnings ratio10.30

Dividend yield

2.80%

Dividend yield2.80%

Average volume

14.55M

Average volume14.55M

High today

$44.25

High today$44.25

Low today

$43.36

Low today$43.36

Open price

$44.02

Open price$44.02

Volume

5.53M

Volume5.53M

52 Week high

$78.38

52 Week high$78.38

52 Week low

$35.12

52 Week low$35.12

NVO News

Simply Wall St 2h

Novo Nordisk Wins UK Approval For Oral Wegovy In Europe First

The UK has approved Novo Nordisk's oral Wegovy pill for chronic weight management. This is the first oral GLP-1 weight-loss therapy cleared in Europe. The dec...

Nasdaq 2h

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

Key Points Eli Lilly currently leads the weight loss market. Novo Nordisk's newer launches could help it make up some ground. Both could capitalize on the gr...

Nasdaq 7h

Novo Nordisk A/S is Attracting Investor Attention: Here is What You Should Know

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could i...

Analyst ratings

54%

of 37 ratings

Buy

37.8%

Hold

54.1%

Sell

8.1%

More NVO News

TipRanks 12h

Novo Nordisk Seeks China Approval for Wegovy Pill, Intensifying Rivalry with Lilly

Novo Nordisk (NVO) is stepping up its competition with rival Eli Lilly (LLY) in China’s oral weight loss drug market. According to a Reuters report, CEO Mike Do...

TipRanks 1d

Novo Nordisk Expands 2026 Share Buyback, Holding 0.8% of Capital in Treasury Shares

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

CNBC 3d

Drugmakers race to find a place in the next wave of obesity drugs

Key Points Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors...

Benzinga 5d

Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet

The approval gives eligible patients a non-injectable alternative to GLP-1-based weight-loss therapies. MHRA Clears First Oral Wegovy Option According to Novo...

TipRanks 5d

Novo Nordisk announces security incident on ‘limited number’ of systems

Novo Nordisk (NVO) said it has identified an IT security incident involving unauthorized access to a “limited number” of internal IT systems. The company said,...

The Wall Street Journal 5d

Novo Nordisk’s Wegovy Weight Loss Pill Approved in the U.K.

Novo Nordisk is looking to regain its lead in the obesity market. George Frey / Bloomberg News Novo Nordisk NOVO.B -0.19 %decrease; down pointing triangle said...

Simply Wall St 7d

Assessing Novo Nordisk Valuation After Recent Share Weakness And GLP‑1 Growth Questions

Advertisement Recent share performance context Novo Nordisk (NYSE:NVO) has been on many investors’ radar after a period of mixed share performance, with the s...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.